Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
grade A 85.34 -2.00% -1.74
INCY closed down 2.0 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical INCY trend table...

Date Alert Name Type % Chg
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Inside Day Range Contraction 0.00%
Mar 21 20 DMA Support Bullish -2.00%
Mar 21 Bollinger Band Squeeze Range Contraction -2.00%
Mar 21 Outside Day Range Expansion -2.00%
Mar 21 Up 3 Days in a Row Strength -2.00%
Mar 21 Up 4 Days in a Row Strength -2.00%
Mar 21 Up 5 Days in a Row Strength -2.00%
Mar 20 Bollinger Band Squeeze Range Contraction -1.12%
Mar 20 Up 3 Days in a Row Strength -1.12%

Older signals for INCY ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Chemistry Biopharmaceutical Chemical Compounds Organic Compounds Solid Tumors Inflammation Psoriasis Pancreatic Cancer Diabetic Nephropathy Clinical Trial Products Janus Kinase Inhibitor Myelofibrosis Essential Thrombocythemia Nitriles Pyrazoles Sulfonamides Thrombocythemia
Is INCY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 88.83
52 Week Low 57.0
Average Volume 1,390,806
200-Day Moving Average 71.0722
50-Day Moving Average 82.1128
20-Day Moving Average 85.2815
10-Day Moving Average 85.326
Average True Range 1.9613
ADX 25.89
+DI 24.1525
-DI 14.7431
Chandelier Exit (Long, 3 ATRs ) 82.9461
Chandelier Exit (Short, 3 ATRs ) 86.8039
Upper Bollinger Band 88.2424
Lower Bollinger Band 82.3206
Percent B (%b) 0.51
BandWidth 6.943827
MACD Line 1.1586
MACD Signal Line 1.2935
MACD Histogram -0.1349
Fundamentals Value
Market Cap 17.56 Billion
Num Shares 206 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -108.03
Price-to-Sales 18.19
Price-to-Book 23.14
PEG Ratio -1.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 88.04
Resistance 3 (R3) 88.33 87.71 87.59
Resistance 2 (R2) 87.71 87.03 87.57 87.44
Resistance 1 (R1) 86.53 86.60 86.22 86.24 87.29
Pivot Point 85.91 85.91 85.76 85.77 85.91
Support 1 (S1) 84.73 85.23 84.42 84.44 83.39
Support 2 (S2) 84.11 84.80 83.97 83.24
Support 3 (S3) 82.93 84.11 83.09
Support 4 (S4) 82.64